The VGF-derived peptide TLQP-62 modulates insulin secretion and glucose homeostasis.

J Mol Endocrinol

Department of Medicine of SystemsUniversity of Rome Tor Vergata, Via Montpellier, 100133 Rome, ItalyInstitute of Cell Biology and NeurobiologyCNR, Rome, ItalyDepartment of Integrative Biology and PhysiologyUniversity of Minnesota, Minneapolis, Minnesota, USAIstituto Superiore di SanitàRome, ItalyEBRI FoundationRome, Italy Department of Medicine of SystemsUniversity of Rome Tor Vergata, Via Montpellier, 100133 Rome, ItalyInstitute of Cell Biology and NeurobiologyCNR, Rome, ItalyDepartment of Integrative Biology and PhysiologyUniversity of Minnesota, Minneapolis, Minnesota, USAIstituto Superiore di SanitàRome, ItalyEBRI FoundationRome, Italy

Published: June 2015

Insulin secretion control is critical for glucose homeostasis. Paracrine and autocrine molecules secreted by cells of the islet of Langerhans, as well as by intramural and autonomic neurons, control the release of different hormones that modulate insulin secretion. In pancreatic islets, the abundant presence of the granin protein VGF (nonacronymic; unrelated to VEGF) suggests that some of its proteolytically derived peptides could modulate hormone release. Thus, in the present study, we screened several VGF-derived peptides for their ability to induce insulin secretion, and we identified the VGF C-terminal peptide TLQP-62 as the most effective fragment. TLQP-62 induced a potent increase in basal insulin secretion as well as in glucose-stimulated insulin secretion in several insulinoma cell lines. We found that this peptide stimulated insulin release via increased intracellular calcium mobilization and fast expression of the insulin 1 gene. Moreover, the peripheral injection of TLQP-62 in mice improved glucose tolerance. Together, the present findings suggest that TLQP-62, acting as an endocrine, paracrine, or autocrine factor, can be considered a new, strong insulinotropic peptide that can be targeted for innovative antidiabetic drug discovery programs.

Download full-text PDF

Source
http://dx.doi.org/10.1530/JME-14-0313DOI Listing

Publication Analysis

Top Keywords

insulin secretion
24
peptide tlqp-62
8
insulin
8
glucose homeostasis
8
paracrine autocrine
8
secretion
6
tlqp-62
5
vgf-derived peptide
4
tlqp-62 modulates
4
modulates insulin
4

Similar Publications

[Research advances in maturity-onset diabetes of the young].

Zhongguo Dang Dai Er Ke Za Zhi

January 2025

Department of Endocrine, Genetics and Metabolism, Children's Hospital Affiliated to Xi'an Jiaotong University, Xi'an 710003, China.

Maturity-onset diabetes of the young (MODY) is a special type of diabetes characterized by clinical features including early onset of diabetes (before 30 years of age), autosomal dominant inheritance, impaired glucose-induced insulin secretion, and hyperglycemia. So far, 14 types of MODY have been reported, accounting for about 1%-5% of the patients with diabetes. MODY often presents with an insidious onset, and although 14 subtypes have been identified for MODY, it is frequently misdiagnosed as type 1 or type 2 diabetes due to overlapping clinical features and high costs and limitations of genetic testing.

View Article and Find Full Text PDF

Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but can give rise to immune-related adverse events such as ICI-related diabetes mellitus (DM).

Case Presentation: We herein present the case of a 59-year-old Japanese man with malignant melanoma who developed ICI-related DM after 18 months of nivolumab treatment. He experienced marked hyperglycemia and diabetic ketoacidosis without a personal or family history of diabetes.

View Article and Find Full Text PDF

Context: Statin treatment lowers low-density lipoprotein (LDL) cholesterol thereby reducing cardiovascular risk. Meta-analyses of clinical trials report a higher risk of new-onset type 2 diabetes with statins. Current clinical evidence regarding effects of statins on insulin sensitivity and beta-cell function is limited.

View Article and Find Full Text PDF

Background: Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder in women of reproductive age. Anovulation is one of the most important clinical features of PCOS, and insulin resistance (IR) is one of the critical pathogenic factors. Woxuanzhongzhou (WXZZ) is a traditional herbal formulation that has shown efficacy in treating PCOS combined with IR, but the underlying mechanism is not clear.

View Article and Find Full Text PDF

Purpose: Our study aimed to discern disparities in metabolic, hormonal profiles, and comorbidities among patients with pituitary Cushing (PC), adrenal Cushing (AC), and Mild autonomous cortisol secretion (MACS).

Methods: We conducted a retrospective analysis involving 76 patients diagnosed with PC ( = 26), AC ( = 21), and MACS ( = 29) at our clinic. We compared the groups' demographic data, clinical characteristics, biochemical profiles, hormonal analyses, and surgical interventions.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!